Literature DB >> 16128810

The HS:1 serostrain of Campylobacter jejuni has a complex teichoic acid-like capsular polysaccharide with nonstoichiometric fructofuranose branches and O-methyl phosphoramidate groups.

David J McNally1, Harold C Jarrell, Jianjun Li, Nam H Khieu, Evgeny Vinogradov, Christine M Szymanski, Jean-Robert Brisson.   

Abstract

Recently, the CPS biosynthetic loci for several strains of Campylobacter jejuni were sequenced and revealed evidence for multiple mechanisms of structural variation. In this study, the CPS structure for the HS:1 serostrain of C. jejuni was determined using mass spectrometry and NMR at 600 MHz equipped with an ultra-sensitive cryogenically cooled probe. Analysis of CPS purified using a mild enzymatic method revealed a teichoic acid-like [-4)-alpha-d-Galp-(1-2)-(R)-Gro-(1-P](n), repeating unit, where Gro is glycerol. Two branches at C-2 and C-3 of galactose were identified as beta-d-fructofuranoses substituted at C-3 with CH(3)OP(O)(NH(2))(OR) groups. Structural heterogeneity was due to nonstoichiometric glycosylation at C-3 of galactose and variable phosphoramidate groups. Identical structural features were found for cell-bound CPS on intact cells using proton homonuclear and (31)P heteronuclear two-dimensional HR-MAS NMR at 500 MHz. In contrast, spectroscopic data acquired for hot water/phenol purified CPS was complicated by the hydrolysis and subsequent loss of labile groups during extraction. Collectively, the results of this study established the importance of using sensitive isolation techniques and HR-MAS NMR to examine CPS structures in vivo when labile groups are present. This study uncovered how incorporation of variable O-methyl phosphoramidate groups on nonstoichiometric fructose branches is used in C. jejuni HS:1 as a strategy to produce a highly complex polysaccharide from its small CPS biosynthetic locus and a limited number of sugars.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16128810     DOI: 10.1111/j.1742-4658.2005.04856.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  17 in total

1.  Mutation of waaC, encoding heptosyltransferase I in Campylobacter jejuni 81-176, affects the structure of both lipooligosaccharide and capsular carbohydrate.

Authors:  Margaret I Kanipes; Erzsebet Papp-Szabo; Patricia Guerry; Mario A Monteiro
Journal:  J Bacteriol       Date:  2006-05       Impact factor: 3.490

2.  Bacteriophage F336 recognizes the capsular phosphoramidate modification of Campylobacter jejuni NCTC11168.

Authors:  Martine C Holst Sørensen; Lieke B van Alphen; Anne Harboe; Jianjun Li; Bjarke Bak Christensen; Christine M Szymanski; Lone Brøndsted
Journal:  J Bacteriol       Date:  2011-09-30       Impact factor: 3.490

3.  Discrimination of major capsular types of Campylobacter jejuni by multiplex PCR.

Authors:  Frédéric Poly; Oralak Serichatalergs; Marc Schulman; Jennifer Ju; Cory N Cates; Margaret Kanipes; Carl Mason; Patricia Guerry
Journal:  J Clin Microbiol       Date:  2011-03-16       Impact factor: 5.948

4.  Campylobacter jejuni drives MyD88-independent interleukin-6 secretion via Toll-like receptor 2.

Authors:  Lorna M Friis; Monika Keelan; Diane E Taylor
Journal:  Infect Immun       Date:  2009-01-12       Impact factor: 3.441

5.  Capsule polysaccharide conjugate vaccine against diarrheal disease caused by Campylobacter jejuni.

Authors:  Mario A Monteiro; Shahida Baqar; Eric R Hall; Yu-Han Chen; Chad K Porter; David E Bentzel; Lisa Applebee; Patricia Guerry
Journal:  Infect Immun       Date:  2008-12-29       Impact factor: 3.441

6.  The Campylobacter jejuni NCTC11168 capsule prevents excessive cytokine production by dendritic cells.

Authors:  Anna Rose; Emily Kay; Brendan W Wren; Margaret J Dallman
Journal:  Med Microbiol Immunol       Date:  2011-08-24       Impact factor: 3.402

7.  Primary isolation strain determines both phage type and receptors recognised by Campylobacter jejuni bacteriophages.

Authors:  Martine C Holst Sørensen; Yilmaz Emre Gencay; Tina Birk; Signe Berg Baldvinsson; Claudia Jäckel; Jens A Hammerl; Christina S Vegge; Horst Neve; Lone Brøndsted
Journal:  PLoS One       Date:  2015-01-13       Impact factor: 3.240

8.  Phase variable expression of capsular polysaccharide modifications allows Campylobacter jejuni to avoid bacteriophage infection in chickens.

Authors:  Martine C Holst Sørensen; Lieke B van Alphen; Christopher Fodor; Shauna M Crowley; Bjarke Bak Christensen; Christine M Szymanski; Lone Brøndsted
Journal:  Front Cell Infect Microbiol       Date:  2012-02-20       Impact factor: 5.293

Review 9.  Campylobacter polysaccharide capsules: virulence and vaccines.

Authors:  Patricia Guerry; Frédéric Poly; Mark Riddle; Alexander C Maue; Yu-Han Chen; Mario A Monteiro
Journal:  Front Cell Infect Microbiol       Date:  2012-02-15       Impact factor: 5.293

10.  Biological roles of the O-methyl phosphoramidate capsule modification in Campylobacter jejuni.

Authors:  Lieke B van Alphen; Cory Q Wenzel; Michele R Richards; Christopher Fodor; Roger A Ashmus; Martin Stahl; Andrey V Karlyshev; Brendan W Wren; Alain Stintzi; William G Miller; Todd L Lowary; Christine M Szymanski
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.